ethyl 1-(4-chloro-2-methylbenzyl)-1H-indazole-3-carboxylate | 1186610-38-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: ethyl 1-(4-chloro-2-methylbenzyl)-1H-indazole-3-carboxylate
• 英文别名: ethyl 1-[(4-chloro-2-methylphenyl)methyl]indazole-3-carboxylate
• CAS: 1186610-38-7
• 化学式: C₁₈H₁₇ClN₂O₂
• 分子量: 328.798
• InChiKey: NIEGYROBDYDGLB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 1-(4-chloro-2-methylbenzyl)-1H-indazole-3-carboxylate 、 碘甲烷 在 magnesium 、 水 、 氯化铵 作用下， 以 乙醚 为溶剂， 反应 24.0h， 生成 2-[1-(4-chloro-2-methylbenzyl)-1H-indazol-3-yl]propan-2-ol
  参考文献：
  名称：

  [EN] 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40
  [FR] NOUVEAUX DÉRIVÉS DE 1-BENZYL-3-HYDROXYMÉTHYLINDAZOLE ET LEUR UTILISATION DANS LE TRAITEMENT DES MALADIES BASÉES SUR L'EXPRESSION DE MCP-1, CX3CR1 ET P40

  摘要：

  公开号：

  WO2009109616A8
• 作为产物：
  描述：

  乙醇 、 陀尼达安 在 硫酸 作用下， 生成 ethyl 1-(4-chloro-2-methylbenzyl)-1H-indazole-3-carboxylate
  参考文献：
  名称：

  [EN] 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40
  [FR] NOUVEAUX DÉRIVÉS DE 1-BENZYL-3-HYDROXYMÉTHYLINDAZOLE ET LEUR UTILISATION DANS LE TRAITEMENT DES MALADIES BASÉES SUR L'EXPRESSION DE MCP-1, CX3CR1 ET P40

  摘要：

  公开号：

  WO2009109616A8

文献信息

• 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40
  申请人：Guglielmotti Angelo

  公开号：US20110082141A1

  公开（公告）日：2011-04-07

  The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to Formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that is active in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40, and to their use in a method for treating or preventing diseases based on the expression of MCP-1, CX3CR1 and p40.

  本发明涉及根据权利要求中所述的式(I)所描述的新型1-苄基-3-羟甲基吲唑衍生物，以及包含它们的制药组合物和与药学上可接受的载体一起使用。此外，本发明还涉及使用1-苄基-3-羟甲基吲唑衍生物制备活性用于治疗基于MCP-1、CX3CR1和p40表达的疾病的制药组合物，并将其用于治疗或预防基于MCP-1、CX3CR1和p40表达的疾病的方法。
• 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40
  申请人：Guglielmotti Angelo

  公开号：US08461194B2

  公开（公告）日：2013-06-11

  The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to Formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that is active in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40, and to their use in a method for treating or preventing diseases based on the expression of MCP-1, CX3CR1 and p40.

  本发明涉及一种新型1-苄基-3-羟甲基吲唑衍生物，其化学式（I）如权利要求中所述，以及包含它们的制药组合物和药用载体。此外，本发明还涉及使用1-苄基-3-羟甲基吲唑衍生物制备对基于MCP-1、CX3CR1和p40表达的疾病具有活性的制药组合物，以及它们在治疗或预防基于MCP-1、CX3CR1和p40表达的疾病的方法中的使用。
• 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40
  申请人：AZIENDE CHIM. RIUN. ANG. FRANC. A.C.R.A.F. S.p.A.

  公开号：US09255073B2

  公开（公告）日：2016-02-09

  The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that is active in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40, and to their use in a method for treating or preventing diseases based on the expression of MCP-1, CX3CR1 and p40.

  本发明涉及一种新型的1-苄基-3-羟甲基吲唑衍生物，其化学式（I）如权利要求书所述，并且涉及包含它们的制药组合物，以及与药学上可接受的载体一起使用的制药组合物。此外，本发明还涉及使用1-苄基-3-羟甲基吲唑衍生物制备对基于 MCP-1、CX3CR1 和 p40 表达的疾病具有活性的制药组合物，并将它们用于治疗或预防基于 MCP-1、CX3CR1 和 p40 表达的疾病的方法。
• 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CXCR1 AND P40
  申请人：Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.

  公开号：EP2262778A2

  公开（公告）日：2010-12-22
• US8461194B2
  申请人：——

  公开号：US8461194B2

  公开（公告）日：2013-06-11